Delisting Determination,The Nasdaq Stock Market, LLC,
February 17, 2009, Introgen Therapeutics, Inc. The Nasdaq Stock
Market, Inc. (the Exchange) has determined to remove from
listing the common stock of Introgen Therapeudics, Inc.
(the Company), effective at the opening of the
trading session on February 27, 2009. Based on a review of
the information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for
listing on the Exchange pursuant to Marketplace Rule
4450(b)(01). The Company was notified of the
Staffs determination on September 4, 2008.
The Company requested a review of the
Staffs determination before the Listing
Qualifications Hearings Panel. Upon review of the
information provided by the Company, the Panel
transferred the Company's securities to the Nasdaq
Capital Market conditioned upon the Company's showing
compliance with Marketplace Rule 4310(c)(02) by
March 3, 2009. ON December 4, 2008, the Company notified
the Panel that it had filed for bankruptcy protection
under Chapter 11 of the U.S. Bankruptcy Code and would
be unable to reestablish compliance with the
Nasdaq listing standards. On December 5, 2008, the Panel
notified the Company that it had determined to delist
the Company's securities and that trading in the Companys
securities would suspended on December 5, 2008.
The Company did not request a review of the Panels
decision by the Nasdaq Listing and Hearing
Review Council. The Listing Council did not call the
matter for review. The Panels Determination to delist
the Company became final on January 20, 2009.